Cordis, a Cardinal Health company, recently announced the full U.S. launch of its Radial 360 portfolio, offering a complete range of products to facilitate the transradial approach (TRA) for interventional cardiology procedures.
Artificial intelligence (AI) solutions provider Aidoc has been granted U.S. Food and Drug Administration (FDA) clearance for an additional product in its expanding suite of AI-based workflow orchestration solutions. The clearance is for Aidoc's Pulmonary Embolism (PE) solution that works with radiologists to flag and triage PE cases in chest computed tomography (CT) scans. The approval comes just weeks after Aidoc closed a $27 million funding round, bringing its total funding to $40 million.
May 15, 2019 — A new study shows electromechanical wave imaging is capable of localizing arrhythmias including atrial ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The ...
May 15, 2019 — Renal artery denervation (RDN) was found to be safe when employed with pulmonary vein isolation (PVI) to ...
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, including ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...
May 15, 2019 — The Heart Rhythm Society (HRS) had 21 late-breaking study presentations at the 2019 Heart Rhythm ...
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD premarket approval (PMA) labeling for the treatment of cardiogenic shock. The expansion extends the duration of support for each pump from 6 days to 14 days.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vein ...
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus statement reflecting a worldwide updated review of the indications, techniques and outcomes of catheter ablation of ventricular arrhythmias (VAs). The expert consensus statement was presented at Heart Rhythm 2019, the HRS’s 40th Annual Scientific Sessions, May 8-11 in San Francisco.
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and management of arrhythmogenic cardiomyopathy (ACM), including findings on genetics and disease mechanisms. Recommendations included in the 2019 HRS Expert Consensus Statement on Evaluation, Risk Stratification, and Management of Arrhythmogenic Cardiomyopathy were presented at Heart Rhythm 2019, the HRS’s 40th Annual Scientific Sessions, May 8-11 in San Francisco.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
May 14, 2019 – Results from new research show that passengers with cardiac implantable electronic devices (CIEDs), such ...
May 13, 2019 — Boston Scientific announced acute results from the UNTOUCHED study evaluating safety and efficacy of the ...
May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their ...